Brief: Pacira Biosciences Inc - Receives Paragraph Iv Notice From Qilu Pharmaceutical
27/10/2025 13:29
Pacira Biosciences Inc PCRX.O: PACIRA BIOSCIENCES INC - RECEIVES PARAGRAPH IV NOTICE FROM QILU PHARMACEUTICAL PACIRA BIOSCIENCES INC - QILU ALLEGES 18 EXPAREL PATENTS INVALID OR UNENFORCEABLE Source text: ID:nGNX261HCp Further company coverage: PCRX.O
Recent news on Pacira Biosciences
See all newsBrief: Pacira Biosciences Inc - Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "For" All Of Pacira's Director Nominees
Brief: Pacira Biosciences Urges Stockholders To Vote "For" Election Of Pacira's Nominees On Blue Proxy Card
Brief: Doma Perpetual Urges Pacira Biosciences Shareholders To Judge Sale Price Adequacy
Brief: Doma Perpetual Capital Management Calls For Removal Of Pacira CEO And Strategic Sale
Brief: Pacira Biosciences Sends Letter To Stockholders Reiterating Superior Qualifications Of Its Board Nominees